Impact of contrast ultrasound diagnosis for patients with liver cancer
Hong-bin Guo, MB\textsuperscript{a}, Jun-hu Wang, MB\textsuperscript{b},\textsuperscript{∗}

Abstract
Background: Numerous studies have reported that contrast ultrasound (CU) can be utilized for diagnosis in patients with liver cancer (LC) accurately. However, no systematic review has addressed to assess its diagnostic impact on patients with LC. Thus, this systematic review will investigate the accurate of CU diagnosis on LC.

Methods: A comprehensive literature search for relevant studies will be performed in the Cochrane Library, EMBASE, MEDILINE, Web of Science, PSYCINFO, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from inceptions to the March 10, 2019. All case-controlled studies investigating the impacts of CU diagnosis on LC will be included in this study. Two researchers will independently carry out study selection, quality assessment, and data extraction. The quality will be assessed by using Quality Assessment of Diagnostic Accuracy Studies tool. Statistical analysis will be conducted by RevMan V.5.3 (Cochrane Community, London, UK) and Stata V.12.0 software (Stata Corp, College Station).

Results: This study will present the accuracy of CU diagnosis for patients with LC through the assessment of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of CU.

Conclusion: The findings of this study will summarize the current evidence for accuracy of CU diagnosis in patients with LC.

Systematic review registration: PROSPERO CRD42019127108.

Abbreviations: CIs = confidence intervals, CU = contrast ultrasound, LC = liver cancer, PRISMA = reporting items for systematic reviews and meta-analysis protocol.

Keywords: contrast ultrasound, liver cancer, sensitivity, specificity

1. Introduction
Liver cancer (LC) is one of the most common digestive system malignant tumors.\textsuperscript{[1,2]} Many factors can cause LC, such as chronic infection with hepatitis B virus or hepatitis C virus, cirrhosis, certain inherited liver diseases, diabetes, nonalcoholic fatty liver disease, exposure to aflatoxins, and excessive alcohol consumption.\textsuperscript{[3–7]} Its mortality rate is relatively high, because it is asymptomatic at early stage and not easy to be identified.\textsuperscript{[8,9]} Most patients are identified as LC with symptoms manifestation until it has advanced to the late stage, which seriously impacts the management and prognosis of the patients.\textsuperscript{[8,9]} Thus, it is very important to diagnosis and to treat it at early stage.\textsuperscript{[10]}

Lots of previous studies have reported that contrast ultrasound (CU) has been used to diagnosis patients with LC,\textsuperscript{[11–20]} However, no study has been conducted to assess the accurate of CU diagnosis on LC. Thus, this study will firstly explore the accurate diagnosis of CU for patients with LC.

2. Methods
2.1. Objective
This study will aim to systematically investigate the value of CU in the diagnosis of patients with LC.

2.2. Ethics and dissemination
This study will not inquire ethic approval, because we will not analyze individual patient data. Its findings will be published on peer-reviewed journals.

2.3. Study registration
This study has been registered on PROSPERO CRD42019127108. We have reported it according to the guideline of preferred reporting items for systematic reviews and meta-analysis protocol (PRISMA-P) statement.\textsuperscript{[21]}

2.4. Eligibility criteria for study selection
2.4.1. Type of studies. Case-controlled studies on the diagnostic accuracy of CU for patients with LC will be included in this study. However, non-clinical researches, non-controlled trials will not be considered for inclusion.
2.4.2. Type of participants. Any patients with histological-proven LC will be included in this study, regardless their race, age, sex, and economic status.

2.4.3. Type of index test. Index test will include CU for the diagnosis of LC. We will exclude the combined diagnosis of CU with other test. Reference test: patients with histological-proven LC will be included in the control group.

2.4.4. Type of outcome measurements. Primary outcomes comprise of sensitivity and specificity. Secondary outcomes include positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio.

2.5. Data sources and search strategy

We will perform a comprehensive literature search for relevant studies from Cochrane Library, EMBASE, MEDILINE, Web of Science, PSYCINFO, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from inceptions to the March 10, 2019. All case-controlled studies exploring the impacts of CU diagnosis on LC will be included in this study. In addition, we will also search reference lists of all eligible studies, and relevant reviews. Search strategy for Cochrane Library is demonstrated in Table 1. We will use identical search strategies for other electronic databases.

2.6. Data collection and management

2.6.1. Study selection. All searched records will be imported into Endnote 7.0 software (Clarivate Analytics, Philadelphia), and duplication studies will be removed. Two researchers will independently scan the titles and abstracts for the remaining records to exclude any irreverent studies. Then, they will read full texts to further determine if those studies can meet the final inclusion criteria. Any disagreements will be solved by a third researcher through discussion. The results of study selection will be summarized according to the PRISMA flow diagram.

2.6.2. Data collection. Two researchers will collect important information and extract data from all eligible studies independently by using predefined data collection form. A third researcher will help to resolve any divergences between 2 researchers through discussion. We will collect following information:

| Number | Search strategy used in Cochrane Library database. |
|--------|---------------------------------------------------|
| 1      | Mesh descriptor: (liver neoplasms) explode all trees |
| 2      | (liver* or (neoplasms*) or (cancer*) or (carcinoma*) or (tumor*) or (tumour*) or (neoplasm*)):ti, ab, kw |
| 3      | Or 1–2 |
| 4      | MeSH descriptor: (ultrasonography) explode all trees |
| 5      | MeSH descriptor: (diagnosis) explode all trees |
| 6      | (contrast*) or (diagnostic imaging *) or (ultrasound*) or (ultrasonics*) or (clinical breast examination*) or (sensitivity*) or (specificity) |
| 7      | Or 4–6 |
| 8      | MeSH descriptor: (case-control studies) explode all trees |
| 9      | (case-control*) or (studies*) or (trials*) or (case*) or (control*) or (study*):ti, ab, kw |
| 10     | Or 8–9 |
| 11     | 3 and 7 and 10 |

2.6.3. Managing missing data. We will contact original authors by email if there is any missing data, or insufficient information. We will conduct data synthesis through available data if the missing data are not available.

2.7. Quality assessment for eligible studies

We will utilize Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool to assess quality for all eligible studies on 4 aspects.[22] Each aspect is assessed with risk of bias, measuring by signaling questions. Two researchers will investigate the quality for each eligible study independently. Any conflicts regarding the quality assessment between 2 researchers will be resolved by discussion with another researcher.

2.8. Statistical analysis

This study will utilize RevMan V.5.3 and Stata V.12.0 software to perform statistical analysis. Stata V.12.0 software will be used to plot estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio. Heterogeneity among eligible studies will be identified by $I^2$ statistic. $I^2 \leq 50\%$ suggests low heterogeneity, and a fixed-effect model will be used. Otherwise, $I^2 > 50\%$ suggests significant heterogeneity, and a random-effect model will be used. In addition, subgroup analysis will be performed to explore any potential causes. Under such situation, bivariate random-effect regression approach will be used for estimating of sensitivity and specificity.

Subgroup analysis will be performed to determine the possible reasons that may cause significant heterogeneity according to the different types of LC, study, and patient characteristics. In addition, we will also carry out sensitivity analysis by eliminating the low quality studies. Furthermore, funnel plots and Egger linear regression test will be performed to identify any feasible reporting bias if >10 eligible studies are included.[23]
3. Discussion

This study will firstly explore the diagnostic accuracy of CU in patients with LC through evaluating its sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio. The results of this study will provide a summary of the updated evidence on the diagnostic accuracy of CU for LC, which is helpful for diagnosis and treatment of LC at early stage.

Author contributions

Conceptualization: Hong-bin Guo, Jun-hu Wang.
Data curation: Hong-bin Guo, Jun-hu Wang.
Formal analysis: Hong-bin Guo.
Funding acquisition: Jun-hu Wang.
Investigation: Jun-hu Wang.
Methodology: Hong-bin Guo.
Project administration: Jun-hu Wang.
Resources: Hong-bin Guo.
Software: Hong-bin Guo.
Supervision: Jun-hu Wang.
Validation: Hong-bin Guo, Jun-hu Wang.
Visualization: Hong-bin Guo, Jun-hu Wang.
Writing – original draft: Hong-bin Guo, Jun-hu Wang.
Writing – review & editing: Hong-bin Guo, Jun-hu Wang.

References

[1] Younossi ZM, Ortonsen M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723–30.
[2] Lee JM, Park JW, Choi BL. 2014 KLSG-NCC Korea Practice Guidelines for the management of hepatocellular carcinoma: HCC diagnostic algorithm. Dig Dis 2014;32:764–77.
[3] Ribes Puig J, Díaz Sanchis M, Bosch José FX. The epidemiology, risk factors and prevention of liver cancer. Gastroenterol Hepatol 1997;20:248–58.
[4] Hagymasi K, Tulassay Z. Epidemiology, risk factors and molecular pathogenesis of primary liver cancer. Orv Hetil 2008;149:541–8.
[5] Smith JW, Kroeker-Lobos MF, Lazo M, et al. Aflatoxin and viral hepatitis exposures in Guatemala: molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS One 2017;12:e0189255.
[6] Suh JK, Lee J, Lee JH, et al. Risk factors for developing liver cancer in people with and without liver disease. PLoS One 2018;13:e0206374.
[7] Ordoñez AO, Simbiri KO, Were V, et al. Risk factors for liver cancer in HIV endemic areas of Western Kenya. Infect Agent Cancer 2018;13:41.
[8] Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 2015;4:39–50.
[9] Mignogna MD, Fedele S, Lo Russo L. The World Cancer report and the burden of oral cancer. Eur J Cancer Prev 2004;13:139–42.
[10] Ryerson AB, Ehemann CR, Altekruse SF, et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016;122:1312–37.
[11] Kong S, Yue X, Kong S, et al. Application of contrast-enhanced ultrasound and enhanced CT in diagnosis of liver cancer and evaluation of radiofrequency ablation. Oncol Lett 2018;16:2434–8.
[12] Sun B, Lv Y, Xing D, et al. Imaging performance and clinical value of contrast-enhanced ultrasonography and computed tomography in the diagnosis of liver cancer. Oncol Lett 2018;15:7669–74.
[13] Xu EJ, Lv SM, Li K, et al. Immediate evaluation and guidance of liver thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia 2018;34:870–6.
[14] Long LL, Peng P, Huang ZK. Early imaging diagnosis of primary liver cancer. Zhonghua Gan Zang Bing Za Zhi 2017;25:329–32.
[15] Yan SY, Zhang Y, Sun C, et al. Comparison of real-time contrast-enhanced ultrasonography and standard ultrasonography in liver cancer microwave ablation. Exp Ther Med 2016;12:1345–8.
[16] Yue WW, Wang S, Xu HX, et al. Parametric imaging with contrast-enhanced ultrasound for differentiating hepatocellular carcinoma from metastatic liver cancer. Clin Hemorheol Microcirc 2016;64:177–88.
[17] Leoni S, Serio I, Pecorelli A, et al. Contrast-enhanced ultrasound in liver cancer. Hepat Oncol 2015;2:51–62.
[18] Xiang Z, Liang Q, Liang C, et al. The correlation of contrast-enhanced ultrasound and MRI perfusion quantitative analysis in rabbit VX2 liver cancer. Cell Biochem Biophys 2014;70:1859–67.
[19] Vezali E, Colombo M. Contrast-enhanced ultrasound to diagnose small liver cancer in cirrhosis: friend or foe? Gastroenterology 2010;139:2209–12.
[20] Xu HX, Lu MD, Xiao SH, et al. Treatment response evaluation with three-dimensional contrast-enhanced ultrasound for liver cancer after local therapies. Eur J Radiol 2010;76:81–8.
[21] Shamsi ER, Moher D, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
[22] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:329–36.
[23] Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882–93.